372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database.
Saved in:
| Title: | 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database. |
|---|---|
| Authors: | Pflumio, C.1 (AUTHOR), Carton, M.2 (AUTHOR), Debled, M.3 (AUTHOR), Cottu, P.H.4 (AUTHOR), Leheurteur, M.5 (AUTHOR), Dalenc, F.6 (AUTHOR), Jacot, W.7 (AUTHOR), Mailliez, A.8 (AUTHOR), Sauterey, B.9 (AUTHOR), Levy, C.10 (AUTHOR), Kaderbhai, C.11 (AUTHOR), Tredan, O.12 (AUTHOR), Gonçalves, A.13 (AUTHOR), Uwer, L.14 (AUTHOR), Robert, M.15 (AUTHOR), Bailleux, C.16 (AUTHOR), Cabel, L.4 (AUTHOR), Delaloge, S.17 (AUTHOR), Bosquet, L.18 (AUTHOR), Petit, T.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS374-S375. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.320 |
